Filter By Category
Archives
Share on -
CAMIDANLUMAB
Generic Name: CAMIDANLUMAB
ABSTRACT -
Camidanlumab is an investigational bispecific immunocytokine combining anti-PD-1 antibody activity with IL-2 receptor agonism to simultaneously block the PD-1 checkpoint and deliver IL-2-mediated T-cell stimulation within the tumour microenvironment. By anchoring IL-2 to the PD-1 complex, it aims to enhance anti-tumour T-cell expansion with reduced systemic IL-2 toxicity. Phase I trials have evaluated it in solid tumours.
DOSAGE -
Intravenous infusion; dose and schedule (Q2W/Q3W) defined in Phase I dose-escalation protocol.
SIDE EFFECTS -
- Immune-related adverse events
- Fatigue
- Cytokine-mediated fever and flu-like symptoms
- Elevated liver enzymes
- Rash
ALLERGIC REACTIONS -
These symptoms may indicate an allergic reaction and require immediate medical attention.
- Infusion hypersensitivity
- Anaphylaxis
- Urticaria
- Angioedema
DRUG INTERACTIONS-
- Additive immune toxicity with checkpoint inhibitors
- Corticosteroids for irAE management may reduce efficacy
- Live vaccines contraindicated
PREAUTONS–
- Comprehensive irAE monitoring per oncology guidelines
- Effective contraception required
- Hepatic and pulmonary function monitoring recommended
- Withhold/discontinue based on irAE severity
WARNINGS –
- Severe immune-mediated reactions including pneumonitis and hepatitis
- Capillary leak syndrome from IL-2 component possible
- Embryo-foetal toxicity — contraindicated in pregnancy
Share on -
. Developed by